Canada Markets closed

Pfizer Inc. (PFE)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
50.11+1.82 (+3.77%)
At close: 04:04PM EDT
49.91 -0.20 (-0.40%)
After hours: 06:24PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close48.29
Open48.55
Bid50.00 x 900
Ask50.00 x 1200
Day's Range48.51 - 50.39
52 Week Range40.94 - 61.71
Volume25,712,169
Avg. Volume20,762,980
Market Cap281.261B
Beta (5Y Monthly)0.68
PE Ratio (TTM)14.31
EPS (TTM)3.50
Earnings DateMay 02, 2022 - May 06, 2022
Forward Dividend & Yield1.60 (3.17%)
Ex-Dividend DateJul 28, 2022
1y Target Est58.49
  • Editor's Pick
    Yahoo Finance

    Vaxxinity CEO on COVID: The market isn't going away and it's going to be a massive commercial opportunity

    Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

  • Zacks

    PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

    Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

  • Reuters

    Biotech stocks pin bounce back hopes on M&A boost

    Plunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner. Pfizer's $5.4 billion acquisition of Global Blood Therapeutics, which was announced on Monday, is the fourth deal in the sector since the pharma giant bought Biohaven for $11.6 billion in May, adding to optimism that large drugmakers are back in the market to pick up cheaper firms. Industry experts predict biotech firms that are closer to getting their product to market or already have a drug approved are likely to become M&A targets for large drugmakers, some of whom are staring at patent expirations of their cash cow drugs.